DBV Technologies | DBVT - Cash And Equivalent


DBV Technologies reported $174.9M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026